The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksB90 Holdings Regulatory News (B90)

Share Price Information for B90 Holdings (B90)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.70
Bid: 2.60
Ask: 2.80
Change: -0.05 (-1.82%)
Spread: 0.20 (7.692%)
Open: 2.75
High: 2.75
Low: 2.65
Prev. Close: 2.75
B90 Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Placing and Subscription, Conversion of CLNs

15 Sep 2023 07:00

RNS Number : 5419M
B90 Holdings PLC
15 September 2023
 

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN, IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, CANADA, JAPAN, AUSTRALIA, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS ANNOUNCEMENT SHOULD BE READ IN ITS ENTIRETY. FURTHER DETAILS OF THE FUNDRAISING ARE SET OUT BELOW.

THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND SHALL NOT CONSTITUTE AN OFFER TO SELL OR ISSUE OR THE SOLICITATION OF AN OFFER TO BUY, SUBSCRIBE FOR OR OTHERWISE ACQUIRE ANY NEW ORDINARY SHARES OF TRACKWISE DESIGNS PLC.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED IN ARTICLE 7 OF THE MARKET ABUSE REGULATION NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED ("MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

15 September 2023

B90 Holdings plc

("B90", the "Company" or "Group")

Placing and Subscription to Raise £2.0 million

Conversion of CLNs and Completion of Acquisition

B90 Holdings plc (AIM: B90), the online marketing and service provision company for the gaming industry, is pleased to announce that it has raised £2.0 million (before expenses) through a placing (the "Placing") and subscription (the "Subscription") (together, the "Fundraising") of 36,731,551 new ordinary shares (the "Fundraising Shares") of no par value each in the capital of the Company ("Ordinary Shares") at a price of 5.44491 pence per Ordinary Share (the "Issue Price").

Key Highlights & Use of Proceeds

The £2.0 million gross proceeds of the Fundraising will be used as follows:

· £1.1 million: investments in inorganic growth opportunities

· £0.4 million: further investment in B90's own assets

· £0.5 million: general working capital and Fundraising expenses

The Issue Price represents a discount of 10 per cent. to 5-day volume weighted average price per Ordinary Share as at close of business on 12 September 2023.

The Fundraising Shares will represent approximately 8.4 per cent. of the Company's enlarged share capital at Admission (as defined below). The Fundraising Shares will be issued under existing authorities. The Fundraising is not underwritten.

Conversion of CLNs

Concurrent with the Fundraising, the Company has served conversion notices to all the holders of the Company's existing convertible loan note ("Loan Notes"), pursuant to which £4,546,352 Loan Notes, together with £180,398 of accrued interest shall be converted at the Issue Price, resulting in the issue of 86,810,441 new Ordinary Shares ("Loan Note Shares"). Following this conversion, no Loan Notes shall remain in issue.

Company Update

Further to its announcement on 12 July 2023, the Company today announces completion of the acquisition of Emwys AB. The balance consideration due to the vendor, Funko International AB, is being settled as to €1.25m in cash together with €1.6 million in equity, which the parties have agreed to issue at the Issue Price, resulting in the vendor receiving 25,271,308 new Ordinary Shares ("Consideration Shares").

To date, the Emwys acquisition has performed positively in line with management's expectations and the Company will now progress full integration of the acquisition and looks forward to providing an update on recent trading along with the interim accounts for the six months ended 30 June 2023, which it expects to announce on or around 29 September 2023.

The Fundraising

The Company has raised £2.0 million (before expenses) through the Placing and the Subscription at the Issue Price. The Fundraising is conditional, amongst other things, upon:

· Receipt by the Company of cleared funds in respect of all the new Ordinary Shares to be issued pursuant to the Subscription;

 

· the Placing Agreement becoming unconditional in all respects save for Admission and not having been terminated in accordance with its terms; and

 

· Admission occurring by no later than 8.00 a.m. on 21 September 2023 (or such later date as Zeus Capital Limited ("Zeus"), Panmure Gordon (UK) Limited ("Panmure"), the Company's joint brokers, Strand Hanson Limited ("Strand Hanson"), the Company's Nominated Adviser, and the Company may agree, not being later than 8.00 a.m. on 30 September 2023).

Mark Blandford, strategic adviser to B90, has subscribed for 14,876,279 new Ordinary Shares in the Subscription at the Issue Price. In addition, his holding of Loan Notes is being converted. As a result, upon Admission Mr Blandford will be interested in 75,756,509 Ordinary Shares which will represent approximately 17.24% per cent. of the Company's enlarged issued ordinary share capital at Admission.

Settlement of liabilities and fees

The Company also agreed to convert certain existing liabilities and to settle certain professional adviser fees, amounting in aggregate to £466,090, through the issue of new Ordinary Shares at the Issue Price, resulting in the issue of 8,560,111 new Ordinary Shares ("Liability and Fee Shares").

Placing Agreement

The Company has entered into a Placing Agreement with Zeus, Panmure and Strand Hanson, pursuant to which Zeus and Panmure, as agents for the Company, have agreed to use their reasonable endeavours to procure Placees for the Placing at the Issue Price. The Placing Agreement contains warranties from the Company in favour of Zeus, Panmure and Strand Hanson in relation to, inter alia, the accuracy of the information contained in the documents relating to the Placing and also certain other matters relating to the Company and its affairs. In addition, the Company has agreed to indemnify Zeus, Panmure and Strand Hanson in relation to certain liabilities that it may incur in respect of the Placing.

Zeus, Panmure and/or Strand Hanson may terminate the Placing Agreement in certain circumstances (including for breach of warranty at any time prior to Admission and in the event of any matter including, without limitation, any change or development in economic, financial, political, diplomatic or other market conditions or any change in any government regulation) occurring which, in the good faith opinion of Zeus, Panmure and Strand Hanson, is (or will be if it occurs) likely materially and prejudicially to affect the financial position or the business or prospects of the Company or otherwise makes it impractical or inadvisable for Zeus, Panmure or Strand Hanson to perform their respective obligations under the Placing Agreement.

Admission and Settlement

Application will be made for the 36,731,551 Fundraising Shares, 86,810,441 Loan Note Shares, 25,271,308 Consideration Shares, and 8,560,111 Liability and Fee Shares (together, the "New Shares") to be admitted to trading on AIM ("Admission"). It is expected that Admission will become effective and dealings in the New Shares will commence at 8.00 a.m. on or around 21 September 2023. These dates and times may change.

All New Shares will be issued fully paid. The New Shares will be allotted and credited as fully paid and will rank pari passu in all respects with the Company's existing Ordinary Shares, including the right to receive all dividends and other distributions declared, made or paid on or after the date on which they are issued.

Total voting rights

On Admission, the Company's total issued share capital will consist of 439,518,227 Ordinary Shares with voting rights. The Company does not hold any Ordinary Shares in treasury and accordingly there are no voting rights in respect of any treasury shares. On Admission, the abovementioned figure of 439,518,227 Ordinary Shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, B90 under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

-Ends-

For further information please contact:

B90 Holdings plc

+44 (0)1624 605 764

Ronny Breivik, Executive Chairman

 

Strand Hanson Limited (Nominated Adviser)

+44 (0)20 7409 3494

James Harris / Richard Johnson / Rob Patrick

 

 

Zeus Capital Limited (Joint Broker)

+44 (0)20 3829 5000

Louisa Waddell / Simon Johnson

 

Panmure Gordon (UK) Limited (Joint Broker)

+44 (0)20 7886 2500

Simon J French

 

Belvedere (Financial PR & IR)

+44 (0)20 3008 6864

John West / Llewellyn Angus

 

About B90 Holdings plc

B90 Holdings plc is a leading company in the online gambling industry, focused on the operation of its own online Sportsbook and Casino product as well as marketing activities for other online gaming companies. We specialise in providing innovative gaming experiences and state-of-the-art technology solutions. With a strong focus on customer satisfaction and responsible gambling practices, B90 Holdings is dedicated to shaping the future of the online gaming landscape.

Each of the times and dates in this Announcement is subject to change. If any of the above times and/or dates change, the revised times and/or dates will be notified by announcement through a Regulatory Information Service. References to time in this Announcement are to London time.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FURLAMBTMTBBMIJ
Date   Source Headline
18th Apr 20247:00 amRNSOddsen.nu goes global
25th Mar 20247:00 amRNSTR-1
25th Mar 20247:00 amRNSTR-1
5th Mar 20247:00 amRNSDirector Dealings
1st Mar 20247:00 amRNSTR-1
1st Feb 20247:00 amRNSTrading Update
22nd Jan 20242:30 pmRNSDirector Dealings
8th Nov 20237:00 amRNSShift to B2B Operations: Relaunch of Bet90.com
30th Oct 20237:00 amRNSGrant of Options
28th Sep 20237:00 amRNSUnaudited Interim Results
15th Sep 20237:00 amRNSPlacing and Subscription, Conversion of CLNs
14th Aug 20237:00 amRNSAppointments: NED; Chief Finance, M&A Dev. Officer
31st Jul 20233:14 pmRNSResult of AGM
17th Jul 202311:28 amRNSPosting of AGM Notice
13th Jul 20237:00 amRNSFURTHER RE SUBSCRIPTION
12th Jul 20237:00 amRNSAcquisition of Emwys; Licence Agreement; CLN issue
30th Jun 20237:01 amRNSFundraising and Board Changes
30th Jun 20237:00 amRNSFinal Results
6th Jun 20237:00 amRNSAppointment of New Broker
28th Apr 20235:02 pmRNSDirector’s purchase of shares
21st Apr 20231:21 pmRNSDirector’s purchase of shares
19th Apr 20237:00 amRNSGrant of Options
5th Apr 20232:10 pmRNSRaise of a further £1.1 million
20th Mar 20234:35 pmRNSPrice Monitoring Extension
21st Feb 20232:05 pmRNSSecond Price Monitoring Extn
21st Feb 20232:00 pmRNSPrice Monitoring Extension
7th Feb 20237:00 amRNSMark Blandford Appointed as Strategic Adviser
6th Feb 20237:00 amRNS£0.5 million Raise and Trading Update
3rd Feb 20237:00 amRNSChange of Adviser
23rd Dec 20227:00 amRNSB90 raises £0.5 million via Convertible Loan Notes
7th Nov 202211:43 amRNSAdjournment of Requisitioned EGM
7th Nov 20227:35 amRNSWithdrawal of Requisition and Directorate Changes
18th Oct 20227:00 amRNSDirector Dealing
17th Oct 202212:18 pmRNSPublication of Circular and Notice of EGM
27th Sep 20222:52 pmRNSUpdate to Requisition to Convene Extraordinary GM
26th Sep 20227:00 amRNSAppointment of Independent Non-Executive Director
23rd Sep 20227:00 amRNSUNAUDITED INTERIM RESULTS
23rd Sep 20227:00 amRNSUNAUDITED INTERIM RESULTS
20th Sep 20223:33 pmRNSExtraordinary General Meeting
14th Sep 20222:22 pmRNSResult of AGM
9th Sep 20227:00 amRNSSubscription to raise £305,000
31st Aug 20227:00 amRNSPosting of AGM Notice
1st Jul 20227:00 amRNSAppointment of New Broker
22nd Jun 20227:00 amRNSGrant of Options
21st Jun 20227:02 amRNSAcquisition of T4U Marketing Ltd
21st Jun 20227:00 amRNSFinal Results
16th May 20227:00 amRNSSubscription and Board Appointment
13th May 20224:03 pmRNSOddsen Acquisition Update
22nd Dec 20217:00 amRNSAcquisition
9th Dec 20217:00 amRNSBoard Changes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.